Stratton Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q4
$10.7M Sell
370,000
-2,000
-0.5% -$55.4K 1.3% 16
2015
Q3
$10.1M Sell
372,000
-14,000
-4% -$396K 1.16% 20
2015
Q2
$10.6M Sell
386,000
-42,200
-10% -$1.19M 0.46% 75
2015
Q1
$11.4M Hold
428,200
0.47% 78
2014
Q4
$9.06M Sell
428,200
-400
-0.1% -$8.94K 0.37% 96
2014
Q3
$10.2M Sell
428,600
-44,000
-9% -$1.01M 0.46% 78
2014
Q2
$10.9M Sell
472,600
-47,900
-9% -$1.06M 0.45% 78
2014
Q1
$11.9M Sell
520,500
-23,000
-4% -$490K 0.55% 66
2013
Q4
$10M Hold
543,500
0.48% 76
2013
Q3
$9.2M Buy
543,500
+9,000
+2% +$151K 0.48% 80
2013
Q2
$8.28M Buy
+534,500
New +$8.9M 0.48% 81

Other funds holding NVO

Stratton Management's NVO Position: Q4 2015 in Review

Stratton Management reduced its Novo Nordisk (NVO) stake by 0.54% in Q4 2015, selling an estimated $55.4K and leaving 370,000 shares worth $10.7M. The position accounts for 1.3% of the portfolio, ranked #16.

Stratton Management first reported a position in NVO in Q2 2013 and has held it in 11 quarters since. The position peaked at $11.9M in Q1 2014. 549 funds tracked by Wall St. Rank hold NVO as of Q4 2015.

  • Stratton Management held 370,000 shares of Novo Nordisk worth $10.7M as of Q4 2015.
  • Stratton Management sold 2,000 Novo Nordisk shares in Q4 2015, an estimated $55.4K.
  • Novo Nordisk made up 1.3% of Stratton Management's portfolio in Q4 2015, its #16 holding.
  • Stratton Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 11 quarters since.
  • Stratton Management's Novo Nordisk position peaked at $11.9M in Q1 2014.
  • 549 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2015.

Based on Stratton Management's 13F filing for Q4 2015, filed 11 Feb 2016.